Chauhan U P, Chander J, Mishra P
Institute of Nuclear Medicine & Allied Sciences, Delhi, India.
Int J Rad Appl Instrum B. 1990;17(4):401-8. doi: 10.1016/0883-2897(90)90108-d.
A new radiopharmaceutical, 99mTc-3-iodo-2,4,6-trimethylphenylcarbamoylmethyl iminodiacetic acid (99mTc-trimethylmonoiodo-IDA) was prepared and evaluated for hepatobiliary scintigraphy. The new agent has less plasma protein binding capacity and greater lipophilicity as compared to that of di-isopropyl-IDA. Hepatobiliary specificity, a short transit time and a high gall bladder-to-liver ratio of the new agent were evident from tissue distribution data in mice. Blood tmax and clearance t1/2 of the radiopharmaceutical were observed at 2 and 3.5 min respectively. The hepatic peak-time tmax (5 min) and release time t1/2 (12.75 min) and release t1/2 (25.00 min) suggest the suitability of this agent for hepatobiliary imaging. Results of hepatobiliary scintigraphy in rabbits have further confirmed the above view.
制备了一种新的放射性药物，99mTc-3-碘-2,4,6-三甲基苯基氨基甲酰甲基亚氨基二乙酸（99mTc-三甲基单碘-IDA），并对其进行肝胆闪烁显像评估。与二异丙基-IDA相比，该新制剂具有较低的血浆蛋白结合能力和较高的亲脂性。从小鼠的组织分布数据可以明显看出，该新制剂具有肝胆特异性、较短的通过时间和较高的胆囊与肝脏比值。放射性药物的血液达峰时间tmax和清除半衰期t1/2分别为2分钟和3.5分钟。肝脏峰时tmax（5分钟）、释放时间t1/2（12.75分钟）和释放t1/2（25.00分钟）表明该制剂适用于肝胆显像。兔的肝胆闪烁显像结果进一步证实了上述观点。
